Targeting angiopoietin-like protein 3 and Interleukin-1β alleviated liver and kidney injury through attenuation of lipotoxicity and normalization of glycolipid metabolism in db/db mice
Authors:
Preprint
- 18 November 2025
- preprint
- Published by Springer Nature in Research Square
Abstract
Objective Concomitant liver and kidney injury is a critical pathological feature of metabolic disorders, but current organ-specific therapies often fail to provide cross-protection. Lipotoxicity is a core mechanism linking damage in both organs. Therefore, this study aimed to investigate whether simultaneously targeting ANGPTL3 and IL-1β could attenuate lipotoxicity and thereby ameliorate concomitant liver and kidney injury. Methods A novel bispecific antibody (BsAb) targeting both ANGPTL3 and IL-1β was generated and characterized by SDS-PAGE, SEC-HPLC, thermal stability analysis, SPR and in vitro bioassay. Then, its protective effects were subsequently studied in the db/db mouse model and the underlying mechanisms were revealed by biochemical examinations, histopathological analysis, immunofluorescence (IF), ELISA, RNA-seq, Immunohistochemical (IHC). Results Administration of the BsAb in db/db mice effectively improved liver and kidney function with alleviated liver steatosis and inflammation, as well as reduced kidney glomerular injury. Furthermore, the treatment attenuated lipotoxicity in both organs and normalized the glycolipid metabolism including restored hepatic glycogen reserves and enhanced renal utilization of fatty acids. Conclusion The results demonstrate that the anti-ANGPTL3/IL-1β BsAb alleviates concomitant liver and kidney injury in db/db mice by attenuating lipotoxicity and normalizing glycolipid metabolism, which highlights a promising therapeutic approach for addressing multi-organ damage in metabolic disorders.Keywords
All Related Versions
- Version 1, 2025-11-18, Research Square
- Published version: Inflammation Research, 75 (1).
This publication has 55 references indexed in Scilit:
- Crosstalk between the liver and kidney in diabetic nephropathyEuropean Journal of Pharmacology, 2022
- Interpreting global trends in type 2 diabetes complications and mortalityDiabetologia, 2021
- VEGF-B antibody and interleukin-22 fusion protein ameliorates diabetic nephropathy through inhibiting lipid accumulation and inflammatory responsesActa Pharmaceutica Sinica B, 2021
- Multi-layered epigenetic regulation of IRS2 expression in the liver of obese individuals with type 2 diabetesDiabetologia, 2020
- Microbially Produced Imidazole Propionate Impairs Insulin Signaling through mTORC1Cell, 2018
- Lipotoxicity and the gut-liver axis in NASH pathogenesisJournal of Hepatology, 2018
- Insulin Resistance, Obesity and Lipotoxicity2017
- Modeling Glucose Metabolism in the KidneyBulletin of Mathematical Biology, 2016
- Restoration of hepatic glycogen deposition reduces hyperglycaemia, hyperphagia and gluconeogenic enzymes in a streptozotocin-induced model of diabetes in ratsDiabetologia, 2011
- ANGPTL3 is increased in both insulin-deficient and -resistant diabetic statesBiochemical and Biophysical Research Communications, 2004